Truist Securities Reiterates Buy Rating on Viridian Therapeutics
Truist Securities maintains its buy stance with a $38 target for Viridian Therapeutics, a 106.86% upside from the current price.
Key Points
- Truist Securities reiterated its buy rating on Viridian Therapeutics, Inc. with a $38 price target on June 30, 2026.
- Truist Securities's $38 price target implies 106.86% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.37 share price.
- Shares of NasdaqCM:VRDN traded at $18.79 on Wednesday, with a market cap of about $2.03 billion.
- Viridian Therapeutics' recent analyst coverage includes RBC Capital and Wedbush, both maintaining buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Truist Securities reiterated its buy rating on Viridian Therapeutics, Inc. (NasdaqCM:VRDN), setting a price target of $38. The stock was trading at $18.79 on Wednesday. This reiteration by analyst Gregory Renza continues to reflect confidence in the company's prospects.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Viridian Therapeutics
FMR LLC increased its stake in Viridian Therapeutics by 994,921 shares, bringing its total to 15,379,377 shares valued at approximately $300.8 million, marking a 6.9% increase. BlackRock, Inc. added 1,399,552 shares, ending with 7,831,475 shares worth about $153.2 million, a 21.8% increase. Bellevue Group AG significantly boosted its holdings by 2,367,617 shares, now holding 6,726,144 shares valued at $131.6 million, reflecting a 54.3% increase. State Street Corp grew its position by 1,206,325 shares to 4,672,885 shares, valued at $91.4 million, a 34.8% increase. Vanguard Capital Management LLC opened a new position with 4,167,201 shares, valued at around $81.5 million.
Viridian Therapeutics, Inc. Stock Down 20.4%
Shares of Viridian Therapeutics, Inc. traded at $18.79 on Wednesday. The company has a market cap of approximately $2.03 billion and a beta of 0.902. Over the past year, the stock has ranged from a low of $13.18 to a high of $34.29. Its 50-day moving average is $16.21, and the 200-day moving average is $24.11. The company maintains a strong liquidity position with a current ratio of 15.15 and a quick ratio of 14.71, although it is not currently profitable, with a negative forward P/E ratio.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Viridian Therapeutics reported revenue of $70.9 million, with a growth rate of 95.8% year-over-year. However, the company has a net margin of 0.0% and a return on equity of -58.1%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Viridian Therapeutics, Inc.
Fairmount Funds Management LLC purchased 1,176,470 shares at an average price of $17.00 on May 11, 2026. Meanwhile, several executives, including Chief Legal Officer Jennifer Tousignant, Chief Operating Officer Thomas Beetham, Chief Financial Officer Seth Harmon, and CEO Stephen Mahoney, sold shares on March 3, 2026, at an average price of $30.19.
Analysts Set New Price Targets
On June 30, 2026, RBC Capital maintained its buy rating and set a price target of $35. Truist Securities also maintained its buy rating with a $38 target, while Wedbush kept its buy rating and a $43 target. Needham maintained a buy rating with a $34 target. The consensus among 16 analysts is a strong buy, with an average target price of $35.50.
About Viridian Therapeutics
Viridian Therapeutics, Inc., based in Waltham, Massachusetts, is a biotechnology company that focuses on developing treatments for serious and rare diseases. The company specializes in IGF-1R therapies for thyroid eye disease and has a pipeline that includes Veligrotrug and Elegrobart. These therapies target IGF-1R for intravenous and subcutaneous administration. Additionally, Viridian is developing treatments for Graves' disease and thyroid eye disease through its anti-TSHR candidate. The company was formerly known as Miragen Therapeutics, Inc.
Bottom Line
Truist Securities' reiterated buy rating and $38 price target suggest continued optimism for Viridian Therapeutics. Investors often track such analyst ratings for insights into potential stock performance. It's important to remember that these ratings are based on backward-looking data and should be considered as part of a broader investment strategy.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.